SHR-A1307 demonstrated strong and sustained anti-tumor activities in EGFR-positive tumors harboring different oncogenic mutations on EGFR, KRAS or PIK3CA. Anti-tumor efficacy of SHR-A1307 correlated with EGFR expression levels in vitro and in vivo, regardless of the mutation status of EGFR-...